Ras, PI(3)K and mTOR signalling controls tumour cell growth
The DOI matches its Crossref record; 86 of the 86 references it cites were found in a registry or an index.
Abstract
All eukaryotic cells coordinate cell growth with the availability of nutrients in their environment. The mTOR protein kinase has emerged as a critical growth-control node, receiving stimulatory signals from Ras and phosphatidylinositol-3-OH kinase (PI(3)K) downstream from growth factors, as well as nutrient inputs in the form of amino-acid, glucose and oxygen availability. Notably, components of the Ras and PI(3)K signalling pathways are mutated in most human cancers. The preponderance of mutations in these interconnected pathways suggests that the loss of growth-control checkpoints and promotion of cell survival in nutrient-limited conditions may be an obligate event in tumorigenesis.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“many common human cancers have mutations in phosphatidylinositol 3-kinase or upstream signaling pathways (13).”
From Digoxin and other cardiac glycosides inhibit HIF-1α synthesis and block tumor growth (2008) · cites this paper as [13]
In the citing paper
“PI3K signaling may be central to linking the common genetic perturbations of cancer, such as RTK mutations and PTEN loss, with altered metabolic processes, including the “lipogenic phenotype” common to many cancers, including GBM (13, 14, 17, 20).”
From An LXR Agonist Promotes Glioblastoma Cell Death through Inhibition of an EGFR/AKT/SREBP-1/LDLR–Dependent Pathway (2011) · cites this paper as [20]
Citations
Cites
Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex
Sarbassov, D. D., Guertin, D. A., Ali, S. M., & Sabatini, D. M. (2005) · Science · doi:10.1126/science.1106148 · Cited by 6,216
TOR signaling in growth and metabolism
Wullschleger, S., Loewith, R., & Hall, M. N. (2006) · Cell · doi:10.1016/j.cell.2006.01.016 · Cited by 5,787 · cited 8×
“So, the PI(3)K heterodimer is recruited to the membrane to generate local pools of PtdIns(3,4,5)P3.”
BackgroundInfluentialAkt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery
Datta, S. R., Dudek, H., Tao, X., Masters, S., Fu, H., Gotoh, Y., & Greenberg, M. E. (1997) · Cell · doi:10.1016/s0092-8674(00)80405-5 · Cited by 5,689
Upstream and downstream of mTOR
Hay, N., & Sonenberg, N. (2004) · Genes & Development · doi:10.1101/gad.1212704 · Cited by 4,181
TSC2 Mediates Cellular Energy Response to Control Cell Growth and Survival
Inoki, K., Zhu, T., & Guan, K.-L. (2003) · Cell · doi:10.1016/s0092-8674(03)00929-2 · Cited by 3,914 · cited 1×
“AMPK inhibits mTOR at least in part by the direct phosphorylation of tuberin ( Box 3 ), and cells that lack tuberin retain activated mTORC1 under conditions of low glucose as well as hypoxi”
BackgroundRAS Is Regulated by the let-7 MicroRNA Family
Johnson, S. M., Grosshans, H., Shingara, J., Byrom, M., Jarvis, R., Cheng, A., Labourier, E., Reinert, K. L., Brown, D., & Slack, F. J. (2005) · Cell · doi:10.1016/j.cell.2005.01.014 · Cited by 3,656 · cited 1×
“In addition to loss of RasGAP function, Ras activity is reported to be elevated through reduced expression of a conserved microRNA (let-7) that targets the 3′ untranslated region of H-ras, N-ras and K-ras messenger RNA”
BackgroundHigh Frequency of Mutations of the PIK3CA Gene in Human Cancers
Samuels, Y., Wang, Z., Bardelli, A., Silliman, N., Ptak, J., Szabo, S., Yan, H., Gazdar, A., Powell, S. M., Riggins, G. J., et al. (2004) · Science · doi:10.1126/science.1096502 · Cited by 3,437
Maehama, T., & Dixon, J. E. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.22.13375 · Cited by 3,104 · cited 1×
“PTEN catalyses removal of the D3 phosphate from PtdIns(3,4,5)P 3 (the reverse of the reaction catalysed by PI(3)K) to limit and ultimately terminate PI(3)K signalling in cell”
BackgroundSarbassov, D. D., Ali, S. M., Kim, D.-H., Guertin, D. A., Latek, R. R., Erdjument-Bromage, H., Tempst, P., & Sabatini, D. M. (2004) · Current Biology · doi:10.1016/j.cub.2004.06.054 · Cited by 2,665
mTOR Inhibition Induces Upstream Receptor Tyrosine Kinase Signaling and Activates Akt
O'Reilly, K. E., Rojo, F., She, Q.-B., Solit, D., Mills, G. B., Smith, D., Lane, H., Hofmann, F., Hicklin, D. J., Ludwig, D. L., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2925 · Cited by 2,561 · cited 1×
“The existence of the S6K-based negative-feedback loop means that prolonged rapamycin treatment will probably lead to enhanced PI(3)K–AKT activation in some tumours, as has been observed in several tumour cell lines grown in culture, and in tissues from patients in clinical trials of rapamycin analogue”
Background
Cited by
Items 601–700 of 1,006
Wong, R. C. B., Tellis, I., Jamshidi, P., Pera, M. F., & Pébay, A. (2007) · Stem Cells and Development · doi:10.1089/scd.2007.0057 · Cited by 62
“Recently, mTOR has also been described as a downstream effector of Erk1/2 signaling (60). mTOR plays an important role in promoting cell growth and proliferation by regulating rDNA transcription and mRNA translation (61). mTOR activation has also been shown to be critical for mediating cell…”
Tolcher, A. W., Goldman, J., Patnaik, A., Papadopoulos, K. P., Westwood, P., Kelly, C. S., Bumgardner, W., Sams, L. L., Geeganage, S., Wang, T., et al. (2014) · European Journal of Cancer · doi:10.1016/j.ejca.2013.11.039 · Cited by 66
“The PI3K/Akt/mTOR signalling pathway is one of the most frequently mutated pathways [1–3], thus making it a target of therapeutic agents.”
BackgroundThe PH domain containing protein CKIP-1 binds to IFP35 and Nmi and is involved in cytokine signaling
Zhang, L., Tang, Y., Tie, Y., Tian, C., Wang, J., Dong, Y., Sun, Z., & He, F. (2006) · Cellular Signalling · doi:10.1016/j.cellsig.2006.11.002 · Cited by 62
Lee, D., Do, I., Choi, K., Sung, C. O., Jang, K., Choi, D.-W., Heo, J. S., Choi, S. H., Kim, J., Park, J. Y., et al. (2011) · Modern Pathology · doi:10.1038/modpathol.2011.133 · Cited by 62
“17 As all of these proteins are regulators of protein synthesis, they can act as proto-oncogenes, and in fact, they are frequently activated in human malignancies”
BackgroundMetabolic reprogramming: a hallmark of viral oncogenesis
Levy, P. L., & Bartosch, B. (2015) · Oncogene · doi:10.1038/onc.2015.479 · Cited by 69
Ion Channel Regulation by Ras, Rho, and Rab Small GTPases
Pochynyuk, O. M., Stockand, J. D., & Staruschenko, A. (2007) · Experimental Biology and Medicine · doi:10.3181/0703-mr-76 · Cited by 61
Zhong, J., Ding, S., Zhang, X., Di, W., Wang, X., Zhang, H., Chen, Y., Zhang, Y., & Hu, Y. (2023) · Frontiers in Bioscience-Landmark · doi:10.31083/j.fbl2802037 · Cited by 67
Li, H., Jin, X., Zhang, Z., Xing, Y., & Kong, X. (2012) · Cell Biochemistry and Function · doi:10.1002/cbf.2917 · Cited by 62
Korkolopoulou, P. A., Levidou, G., Trigka, E., Prekete, N., Κάρλου, Μ., Thymara, I., Sakellariou, S., Fragkou, P. C., Isaiadis, D., Pavlopoulos, P. M., et al. (2012) · British Journal of Urology · doi:10.1111/j.1464-410x.2012.11569.x · Cited by 63
Sánchez-Hernández, I., Baquero, P., Calleros, L., & Chiloeches, A. (2011) · Cancer Letters · doi:10.1016/j.canlet.2011.09.037 · Cited by 68
Hirashima, K., Baba, Y., Watanabe, M., Karashima, R.-I., Sato, N., Imamura, Y., Hiyoshi, Y., Nagai, Y., Hayashi, N., Iyama, K.-I., et al. (2010) · Annals of Surgical Oncology · doi:10.1245/s10434-010-1040-1 · Cited by 65
Karanam, G., & Arumugam, M. K. (2020) · Molecular Biology Reports · doi:10.1007/s11033-020-05407-5 · Cited by 62
Ninov, N., Manjón, C., & Martín-Blanco, E. (2009) · PLoS Biology · doi:10.1371/journal.pbio.1000079 · Cited by 61
“Unconventional cell cycles without G1 are also characteristic of mouse and human embryonic stem cells (ESC) as well as some tumor cells (reviewed in [4,5]).”
BackgroundEpidemiology, Aetiology, and Pathogenesis of Renal Cell Carcinoma
Protzel, C., Maruschke, M., & Hakenberg, O. W. (2012) · European Urology Supplements · doi:10.1016/j.eursup.2012.05.002 · Cited by 71
“One important target again is mTOR [36,48].”
Feng, W., Duan, X., Liu, J., Xiao, J., & Brown, R. E. (2009) · PubMed Central · Cited by 72
Splicing Regulators and Their Roles in Cancer Biology and Therapy
da Silva, M. R., Moreira, G. A., da Silva, R. A. G., Barbosa, É. D. A. A., Siqueira, R. P., Teixeira, R. R., de Almeida, M. R., Silva‐Júnior, A., Fietto, J. L. R., & Bressan, G. C. (2015) · BioMed Research International · doi:10.1155/2015/150514 · Cited by 64
“The PI3K/AKT/mTOR and RAS/RAF/MEK/ERK pathways (Figure 2) are the most frequently impaired signaling pathways in cancer [111, 112].”
Small molecules targeting phosphoinositide 3-kinases
Wu, P., & Hu, Y. (2012) · MedChemComm · doi:10.1039/c2md20044a · Cited by 62
Ripple, M. O., Kim, N.-J., & Springett, R. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.438945 · Cited by 73
“Glutamine enters the cell and activates mTOR (30–31), which is the master regulator of cell growth (32).”
BackgroundFisher, K. W., Das, B., Kortum, R. L., Chaika, O. V., & Lewis, R. E. (2011) · Molecular and Cellular Biology · doi:10.1128/mcb.05255-11 · Cited by 68
“that help coordinate their actions (54).”
Cotargeting the PI3K and RAS Pathways for the Treatment of Neuroendocrine Tumors
Valentino, J. D., Li, J., Zaytseva, Y. Y., Mustain, W. C., Elliott, V. A., Kim, J. T., Harris, J. W., Campbell, K., Weiss, H. L., Wang, C., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1897 · Cited by 63
“The RAS/MEK pathway also has a well-defined role in cancer development and progression (13) and is often closely integrated with the PI3K pathway (14).”
Rapamycin Is a Potent Inhibitor of Skin Tumor Promotion by 12- O -Tetradecanoylphorbol-13-Acetate
Checkley, L. A., Rho, O., Moore, T., Hursting, S., & DiGiovanni, J. (2011) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-10-0375 · Cited by 60
“The phosphoinositide-3-kinase (PI3K)/Akt signaling pathway is one of the most commonly altered pathways found in human tumors (1, 2).”
BackgroundRapalogs Efficacy Relies on the Modulation of Antitumor T-cell Immunity
Beziaud, L., Mansi, L., Ravel, P., Joseph, E. L. M., Laheurte, C., Rangan, L., Bonnefoy, F., Pallandre, J., Boullerot, L., Gamonet, C., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-2452 · Cited by 61
“Oncogenic activation of mTOR signaling induces several processes required for cancer cells growth, survival, and proliferation (2).”
BackgroundMolecular-targeted first-line therapy for advanced gastric cancer
Song, H., Zhu, J., & Lu, D. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011461.pub2 · Cited by 62
Wu, C., Qiu, S.-L., Liu, P., Ge, Y.-Q., & Gao, X.-F. (2018) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2017.09.033 · Cited by 56
Kaneko, R., Tsuji, N., Asanuma, K., Tanabe, H., Kobayashi, D., & Watanabe, N. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m610350200 · Cited by 60
Small molecule compounds targeting the p53 pathway: are we finally making progress?
Yu, X., Narayanan, S., Vazquez, A., & Carpizo, D. R. (2014) · Apoptosis · doi:10.1007/s10495-014-0990-3 · Cited by 59
“The PI3K/mTOR pathway is activated in large number of cancers which provides a rationale for the combination of a p53 modulating drug and an mTOR inhibitor [78, 106, 107].”
BackgroundAnimal (De)liberation: Should the Consumption of Animal Products Be Banned?
Deckers, J. (2016) · Ubiquity Press eBooks · doi:10.5334/bay · Cited by 65
Enhancing mTOR-targeted cancer therapy
Wang, X., & Sun, S.-Y. (2009) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728220903225008 · Cited by 58
“It plays a central role in regulating cell growth, proliferation and survival, in part by regulation of translation initiation, primarily through interactions with other proteins such as raptor (forming mTOR complex 1, mTORC1) and rictor (forming mTOR complex 2, mTORC2) [2-4].”
BackgroundPappas, G., Zumstein, L. A., Munshi, A., Hobbs, M. L., & Meyn, R. E. (2007) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7701050 · Cited by 59
Dai, C., Zhang, B., Liu, X., Ma, S., Yang, Y., Yao, Y., Feng, M., Bao, X., Li, G., Wang, J., et al. (2013) · Endocrinology · doi:10.1210/en.2012-1908 · Cited by 62
Abdi, A., Tahoori, M. B., & Emamian, E. S. (2008) · Science Signaling · doi:10.1126/scisignal.2000008 · Cited by 62
Vahidnezhad, H., Youssefian, L., & Uitto, J. (2015) · Journal of Investigative Dermatology · doi:10.1038/jid.2015.331 · Cited by 65
Liu, X., Wu, J., Zhang, D., Wang, K., Duan, X., & Zhang, X. (2018) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2018/6517034 · Cited by 61
“AKT activates a series of downstream factors by phosphorylation and therefore modulates cellular metabolism that is rewired in cancer cells [75].”
BackgroundEvodiamine activates cellular apoptosis through suppressing PI3K/AKT and activating MAPK in glioma
Wang, R., Deng, D., Shao, N., Xu, Y., Xue, L., Peng, Y., Liu, Y., & Zhi, F. (2018) · OncoTargets and Therapy · doi:10.2147/ott.s155275 · Cited by 63
“25,26 Western blot analyses indicated that Evo treatment considerably reduced PI3K/AKT pathway activation in GBM cells.”
Zibelman, M. R., Wong, Y., Devarajan, K., Malizzia, L., Corrigan, A., Olszanski, A. J., Denlinger, C. S., Roethke, S. K., Tetzlaff, C. H., & Plimack, E. R. (2015) · Investigational New Drugs · doi:10.1007/s10637-015-0261-3 · Cited by 60
“[1–3] Altered functioning of this pathway has been linked to tumorigenesis in several human cancers.[2, 4, 5] Inhibition of mTOR directly decreases gene translation, thus reducing protein synthesis and in turn leading to delayed or arrested progression through the cell cycle.”
BackgroundWang, Y.-C., Kulp, S. K., Wang, D.-S., Yang, C.-C., Sargeant, A. M., Hung, J., Kashida, Y., Yamaguchi, M., Chang, G.-D., & Chen, C. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-1336 · Cited by 62
“are frequent features of many types of human cancers (7, 8).”
BackgroundLin, Z., Wan, X. H., Jiang, R., Deng, L., Gao, Y., Tang, J., Yu, Y., Zhao, W., Yan, X., Yao, K., et al. (2014) · Journal of Virology · doi:10.1128/jvi.01867-14 · Cited by 60
“in the phosphatidylinositol 3-kinase (PI3K)/Akt pathway (15, 16),”
BackgroundExtracellular and intracellular sphingosine-1-phosphate in cancer
Yester, J., Tizazu, E., Harikumar, K. B., & Kordula, T. (2011) · Cancer and Metastasis Reviews · doi:10.1007/s10555-011-9305-0 · Cited by 62
“mTOR regulates cell metabolism and growth by integrating signals from growth factor inputs, as well as nutrient availability, and thus, mTOR is a molecule of great interest in cancer research [261].”
Dynamic Switch of Negative Feedback Regulation in Drosophila Akt–TOR Signaling
Kockel, L., Kerr, K. S., Melnick, M., Brückner, K., Hebrok, M., & Perrimon, N. (2010) · PLoS Genetics · doi:10.1371/journal.pgen.1000990 · Cited by 64
“Ectopic activation of the core Akt-TOR signaling pathway by a variety of mechanisms is a frequent event in cancer biology [18,34].”
BackgroundInfluential27-hydroxycholesterol: A novel player in molecular carcinogenesis of breast and prostate cancer
Marwarha, G., Raza, S., Hammer, K. D. P., & Ghribi, O. (2017) · Chemistry and Physics of Lipids · doi:10.1016/j.chemphyslip.2017.05.012 · Cited by 64
Leung, E. L., Luo, L. X., Liu, Z. Q., Wong, V. K. W., Lu, L., Xie, Y., Zhang, N., Qu, Y. Q., Fan, X., Li, Y., et al. (2018) · Cell Death and Disease · doi:10.1038/s41419-017-0065-9 · Cited by 60
Gu, X., Qiu, Y., Lin, M., Cui, K., Chen, G., Chen, Y., Fan, C., Zhang, Y., Xu, L., Chen, H., et al. (2019) · Nano Letters · doi:10.1021/acs.nanolett.9b01065 · Cited by 61
Kasitinon, S. Y., Eskiocak, U., Martin, M., Bezwada, D., Khivansara, V., Tasdogan, A., Zhao, Z., Mathews, T. P., Aurora, A. B., & Morrison, S. J. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.07.086 · Cited by 62
“Trametinib blocked the increases in ERK, TSC2, and S6K phosphorylation in MCOLN1-deficient clones (Figures 3D–3F), suggesting that the increase in mTORC1 signaling was caused by the phosphorylation and inactivation of TSC2 by the MAPK pathway, as has been observed (Johannessen et al., 2005; Ma et al., 2005; Shaw and C…”
ResultGowan, S. M., Hardcastle, A., Hallsworth, A., Valenti, M. R., Hunter, L.-J. K., Brandon, A. K. D. H., Garrett, M. D., Raynaud, F. I., Workman, P., Aherne, W., et al. (2007) · Assay and Drug Development Technologies · doi:10.1089/adt.2006.044 · Cited by 60
Soulard, A., & Hall, M. N. (2007) · Cell · doi:10.1016/j.cell.2007.04.010 · Cited by 58
Son, M. K., Jung, K. H., Hong, S., Lee, H.-S., Zheng, H., Choi, M., Seo, J. H., Suh, J., & Hong, S. (2012) · Food Chemistry · doi:10.1016/j.foodchem.2012.07.096 · Cited by 59
Li, Y., Wang, X., Yue, P., Tao, H., Ramalingam, S. S., Owonikoko, T. K., Deng, X., Wang, Y., Fu, H., Khuri, F. R., et al. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.463679 · Cited by 59
Melnik, B. C. (2012) · Journal of Obesity · doi:10.1155/2012/197653 · Cited by 63
“Exaggerated formula-induced mTORC1 signalling appears to be the most critical factor for the early development of childhood obesity and other mTORC1driven chronic diseases of civilization especially T2D and cancer [135–139].”
BackgroundThe mTOR signaling pathway as a treatment target for intracranial neoplasms
Pachow, D., Wick, W., Gutmann, D. H., & Mawrin, C. (2014) · Neuro-Oncology · doi:10.1093/neuonc/nou164 · Cited by 64
Kang, J. I., Hong, J., Lee, H., Bae, S. Y., Jung, C., Park, H. J., & Lee, S. K. (2015) · PLoS ONE · doi:10.1371/journal.pone.0144368 · Cited by 59
“Tuberous sclerosis complex 2 (TSC2) tumor suppressor and its obligate partner TSC1 are reported as upstream components of mTORC1 [35].”
BackgroundWang, Y., Zhao, L., Han, X., Wang, Y., Mi, J., Wang, C., Sun, D., Fu, Y., Zhao, X., Guo, H.-D., et al. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2019.01487 · Cited by 58
“Signaling through CXCR4 activates the PI3K/AKT pathway (26), which is involved in the initiation and progression of breast tumors and regulates various cellular functions, including survival, proliferation, and metabolism (31, 32).”
BackgroundCincin, Z. B., Kiran, B., Baran, Y., & Cakmakoglu, B. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.04.020 · Cited by 56
Antagonism of the ATP-gated P2X7 receptor: a potential therapeutic strategy for cancer
Drill, M., Jones, N. C., Hunn, M., O'Brien, T. J., & Monif, M. (2021) · Purinergic Signalling · doi:10.1007/s11302-021-09776-9 · Cited by 58
Elis, W., Triantafellow, E., Wolters, N. M., Sian, K. R., Caponigro, G., Borawski, J. A., Gaither, L. A., Murphy, L. O., Finan, P. M., & MacKeigan, J. P. (2008) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-07-0262 · Cited by 63
“The activation of phosphoinositide 3-kinases (PI3K) in response to extracellular stimuli and the subsequent generation of 3¶-phosphorylated phosphoinositides as intracellular second messengers is a hallmark of many signaling pathways (1).”
BackgroundeIF4E Phosphorylation in Prostate Cancer
D'Abronzo, L. S., & Ghosh, P. (2018) · Neoplasia · doi:10.1016/j.neo.2018.04.003 · Cited by 63
“The mTOR pathway has been implicated in the drive and maintenance of cell survival and proliferation of different types of cancer cells [22,23] and in epithelial derived cancers such as PCa, the PI3K/mTOR pathway is notoriously hyperactive [24].”
Oncogenic mutations in extramammary Paget's disease and their clinical relevance
Kang, Z., Xu, F., Zhang, Q., Wu, Z., Zhang, X., Xu, J., Luo, Y., & Guan, M. (2012) · International Journal of Cancer · doi:10.1002/ijc.27738 · Cited by 58
“The key components including RAS and RAF in RAS/RAF signaling pathway, PIK3CA and AKT1 in PI3K/AKT pathway, are all involved in the corresponding cell biological function.(9,10) In addition, interacting with EGFR signaling, WNT pathway also plays a pivotal role in promoting cell proliferation and metastasis.”
BackgroundMinimally invasive biomarkers for detection and staging of colorectal cancer
Booth, R. A. (2007) · Cancer Letters · doi:10.1016/j.canlet.2006.12.021 · Cited by 62
Ezponda, T., Pajares, M. J., Agorreta, J., Echeveste, J. I., López-Picazo, J. M., Torre, W., Pı́o, R., & Montuenga, L. M. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0076 · Cited by 55
Lupton, C. J., Bayly-Jones, C., D’Andrea, L., Huang, C., Schittenhelm, R. B., Venugopal, H., Whisstock, J. C., Halls, M. L., & Ellisdon, A. M. (2021) · Nature Structural & Molecular Biology · doi:10.1038/s41594-021-00687-2 · Cited by 58
Galluzzi, L., Santi, M. D., Crinelli, R., Marco, C. D., Zaffaroni, N., Duranti, A., Brandi, G., & Magnani, M. (2012) · PLoS ONE · doi:10.1371/journal.pone.0043249 · Cited by 64
“The kinase mTOR is also a critical regulator of autophagy, with the activated mTOR acting as an autophagy inhibitor [26].”
BackgroundZhou, P., Hu, W., Zhang, X., Wang, W., & Zhang, L. (2016) · Mediators of Inflammation · doi:10.1155/2016/7201549 · Cited by 57
“Phosphatidylinositol 3-kinase/protein kinase B (PI3K/ Akt) signaling pathway is a major signaling cascade that promotes cell survival and proliferation [18].”
BackgroundWang, X., Goldstein, D., Crowe, P., & Yang, J.-L. (2016) · OncoTargets and Therapy · doi:10.2147/ott.s94745 · Cited by 52
Becher, O. J., Millard, N. E., Modak, S. I., Kushner, B. H., Haque, S. S., Spasojević, I., Trippett, T. M., Gilheeney, S. W., Khakoo, Y., Lyden, D. C., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0178593 · Cited by 59
Adiponectin inhibits high glucose‐induced angiogenesis via inhibiting autophagy in RF/6A cells
Li, R., Du, J., Yao, Y., Yao, G., & Wang, X. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.28659 · Cited by 55
“The PI3K/AKT/mTOR signaling pathway can regulate the protein synthesis, cell cycle, and cell metabolism through coordinating the phosphorylation of its downstream protein to control the growth, proliferation, apoptosis, and autophagy of cells (Shaw & Cantley, 2006).”
BackgroundMammalian target of rapamycin (mTOR) pathway signalling in lymphomas
Drakos, E., Rassidakis, G. Z., & Medeiros, L. J. (2008) · Expert Reviews in Molecular Medicine · doi:10.1017/s1462399408000586 · Cited by 59
New phosphatidylinositol 3-kinase inhibitors for cancer
Bowles, D. W., & Jimeno, A. (2011) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2011.562192 · Cited by 58
“In the non-canonical pathway, PI3K may also be directly activated by Ras [14] or GPCR interactions with the p110 catalytic subunit [4].”
BackgroundHe, P., Ma, J., Liu, Y., Deng, H., & Dong, W. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.01326 · Cited by 54
“Activated AKT controls a variety of biological reactions, such as inhibiting apoptosis by directly phosphorylating apoptotic signal proteins or regulating the activity of transcription factors (Shaw and Cantley, 2006).”
BackgroundKim, A., Lee, J. J., Lee, S., Kim, C., Lee, S., Jang, W., & Park, S. (2013) · International Journal of Cancer · doi:10.1002/ijc.28073 · Cited by 58
“These mutations result in PI3K/AKT pathway stimulation and promote cell growth in various cancers.(9,10) Thus, the majority of CRC patients have genetic alterations that converge on signal transduction pathways to cause increased expression of AKT protein.”
BackgroundDownregulation of Beclin1 and Impairment of Autophagy in a Small Population of Colorectal Cancer
Chen, Z., Li, Y., Zhang, C., Yi, H., Wu, C., Wang, J., Liu, Y., Tan, J., & Wen, J. (2013) · Digestive Diseases and Sciences · doi:10.1007/s10620-013-2732-8 · Cited by 57
“PI3-kinase pathway, leading to activation of mTOR and thus suppression of autophagy [27, 28].”
BackgroundKim, E., Kim, H., Koh, J. S., Kim, M. S., Kim, K., Lee, J. I., Moon, N. M., Ko, E., & Noh, W. C. (2010) · Breast Cancer Research and Treatment · doi:10.1007/s10549-010-1315-z · Cited by 56
“The mammalian target of rapamycin (mTOR) is a protein kinase of the phosphatidylinositol 3-kinase (PI3 K)/Akt signaling pathway [ 1 , 2]. There is growing evidence that the PI3 K/Akt/mTOR pathway is frequently deregulated during tumorigenesis, via genetic and epigenetic alterations, contributing to the development and…”
BackgroundFalasca, M., Chiozzotto, D., Godage, H. Y., Mazzoletti, M., Riley, A. M., Previdi, S., Potter, B. V. L., Broggini, M., & Maffucci, T. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605408 · Cited by 52
“Deregulation of PI3K-dependent signalling pathways is linked to the development of cancer (Maehama and Dixon, 1999; Shayesteh et al, 1999; Vivanco and Sawyers, 2002; Bader et al, 2005; Shaw and Cantley, 2006; Vogt et al, 2007) and to increased resistance to treatment with chemotherapeutic agents (Clark et al, 2002; Li…”
BackgroundRen, H. (2010) · International Journal of Oncology · doi:10.3892/ijo.2010.861 · Cited by 54
Liu, Y., Wan, W.-Z., Li, Y., Zhou, G.-L., & Liu, X. (2016) · Oncotarget · doi:10.18632/oncotarget.12742 · Cited by 56
“Discovery of 9-(6-aminopyridin3-yl)-1-(3- (trifluoromethyl) phenyl)benzo [h][1,6] naphthyridin-2( 1H)-one (Torin2) as a potent, selective, and orally available mammalian target of rapamycin (mTOR) inhibitor for treatment of cancer.”
BackgroundMoriai, R., Tsuji, N., Moriai, M., Kobayashi, D., & Watanabe, N. (2008) · Breast Cancer Research and Treatment · doi:10.1007/s10549-008-0164-5 · Cited by 54
Vu, N., Kim, M., Stephenson, D., MacKnight, H. P., & Chalfant, C. E. (2022) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-22-0085 · Cited by 60
Jung, J., Overgaard, N. H., Burke, M., Isbel, N. M., Frazer, I. H., Simpson, F., & Wells, J. W. (2015) · International Journal of Cancer · doi:10.1002/ijc.29450 · Cited by 55
“The mTOR signaling pathway is important in regulating cell cycle progression, metabolism and protein synthesis.(33) Rapamycin is thought to inhibit mTOR solely via the Raptor-dependent pathway, thus primarily inhibiting the mTORC1 protein (Fig.”
BackgroundMAPK/ERK signaling pathway-induced hyper-O-GlcNAcylation enhances cancer malignancy
Zhang, X., Ma, L., Qi, J., Shan, H., Yu, W., & Gu, Y. (2015) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-015-2542-8 · Cited by 54
Lee, H., Jung, K. H., Jeong, Y., Hong, S., & Hong, S. (2012) · Cancer Letters · doi:10.1016/j.canlet.2012.08.020 · Cited by 56
Preferential chemosensitization of PTEN‐mutated prostate cells by silencing the Akt kinase
Priulla, M., Calastretti, A., Bruno, P., Azzariti, A., Paradiso, A., Canti, G. L., & Nicolin, A. (2007) · The Prostate · doi:10.1002/pros.20566 · Cited by 53
“Akt is activated in themajority of human tumors and occupies a pivotal position in oncogenic signaling and drug resistance [36].”
Molecular targeted therapies for pancreatic cancer
Borja–Cacho, D., Jensen, E. H., Saluja, A. K., Buchsbaum, D. J., & Vickers, S. M. (2008) · The American Journal of Surgery · doi:10.1016/j.amjsurg.2008.04.009 · Cited by 56
Chen, Y., Wei, M., Wang, C.-W., Lee, H.-W., Pan, S., Gao, M., Kuo, S., Cheng, A., & Teng, C. (2014) · Cancer Letters · doi:10.1016/j.canlet.2014.12.015 · Cited by 55
Nutrient Restriction and Radiation Therapy for Cancer Treatment: When Less Is More
Champ, C. E., Baserga, R., Mishra, M. V., Jin, L., Sotgia, F., Lisanti, M. P., Pestell, R. G., Dicker, A. P., & Simone, N. L. (2013) · The Oncologist · doi:10.1634/theoncologist.2012-0164 · Cited by 53
BRAF mutations in non-small cell lung cancer.
Luk, P. P., Yu, B., Ng, C. C., Mercorella, B., Selinger, C. I., Lum, T., Kao, S., O’Toole, S. A., & Cooper, W. A. (2015) · PubMed Central · doi:10.3978/j.issn.2218-6751.2014.08.08 · Cited by 53
Sun, Z., Wang, Z., Liu, X., & Wang, D. (2014) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000000172 · Cited by 55
Indole-3-Carbinol and Its Role in Chronic Diseases
Licznerska, B. E., & Baer‐Dubowska, W. (2016) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-41334-1_6 · Cited by 55
Sarwar, M., Khaja, A. S. S., Aleskandarany, M. A., Karlsson, R. T. G., Althobiti, M. M., Ødum, N., Mongan, N. P., Dizeyi, N., Johnson, H., Green, A. R., et al. (2018) · Oncogene · doi:10.1038/s41388-018-0438-2 · Cited by 53
mTOR pathway in renal cell carcinoma
Hanna, S. C., Heathcote, S. A., & Kim, W. Y. (2008) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.8.2.283 · Cited by 55
Pulmonary lymphangioleiomyomatosis (LAM): Progress and current challenges
Goncharova, E. A., & Krymskaya, V. P. (2007) · Journal of Cellular Biochemistry · doi:10.1002/jcb.21419 · Cited by 56
Leontieva, O. V., Paszkiewicz, G. M., & Blagosklonny, M. V. (2012) · Aging · doi:10.18632/aging.100528 · Cited by 51
“TOR is conserved from yeast to mammals, including humans [24-26].”
BackgroundHwang, J. W., Baek, Y.-M., Yang, K. E., Yoo, H., Cho, C.-K., Lee, Y.-W., Park, J., Eom, C., Lee, Z.-W., Choi, J.-S., et al. (2012) · Integrative Cancer Therapies · doi:10.1177/1534735412442380 · Cited by 52
“Excess PI3K/AKT signaling, an mTOR activator, is a feature of most, if not all, cancers.(38) AKT is activated by phosphoinositide 3-kinase (PI3K) and causes several cancer-related responses, including increased cell growth and proliferation, a shift to glycolytic metabolism, and increased cell migration.”
BackgroundNovel therapeutic targets in advanced urothelial carcinoma
Rouanne, M., Loriot, Y., Lebrét, T., & Soria, J. (2015) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2015.10.021 · Cited by 55
MicroRNA-181b inhibits glycolysis in gastric cancer cells via targeting hexokinase 2 gene
Li, L., Yang, Y., Chen, H., Zhang, L., Pan, D., & Xie, W. (2016) · Cancer Biomarkers · doi:10.3233/cbm-160619 · Cited by 52
Liu, S., Huang, J., Zhang, Y., Liu, Y., Zuo, S., & Li, R. (2019) · Aging · doi:10.18632/aging.102485 · Cited by 52
“Phosphoinositide 3-kinases (PI3Ks) affect many cellular biologic functions regarding intracellular signal transduction pathways and are one of the most common signaling pathways that are deregulated in cancer [20].”
BackgroundJaglanian, A., & Tsiani, E. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21030810 · Cited by 56
Cheng, K., Liu, C., & Rao, G. (2020) · Current Medicinal Chemistry · doi:10.2174/0929867327666200514082425 · Cited by 55
Current Evidence of the Role of the Myokine Irisin in Cancer
Tsiani, E., Tsakiridis, N., Kouvelioti, R., Jaglanian, A., & Klentrou, P. (2021) · Cancers · doi:10.3390/cancers13112628 · Cited by 51
Histone H3K27 demethylase KDM6A is an epigenetic gatekeeper of mTORC1 signalling in cancer
Revia, S., Seretny, A., Wendler, L., Banito, A., Eckert, C., Breuer, K., Mayakonda, A., Lutsik, P., Evert, M., Ribback, S., et al. (2021) · Gut · doi:10.1136/gutjnl-2021-325405 · Cited by 59
Metformin and Cancer Stem Cells: Old Drug, New Targets
Bednar, F., & Simeone, D. M. (2012) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-12-0026 · Cited by 51
“Both of these pathways directly inhibit the function of the tuberous sclerosis complex (TSC; comprising TSC-1 and -2) by phosphorylating TSC-2, which in turn leads to the activation of the mTOR complex 1 (mTORC1) by the GTPase Rheb (11).”
BackgroundNCI's provocative questions on cancer: some answers to ignite discussion
Blagosklonny, M. V. (2011) · Oncotarget · doi:10.18632/oncotarget.432 · Cited by 54
“Noteworthy, the activation PI3K/mTOR pathway by mutations (Figure 2) is one of the most universal alterations in cancer [87, 274-284].”
BackgroundWang, H. (2025) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2025.103614 · Cited by 54
Metadata
- Authors
- Shaw, R. J., & Cantley, L. C.
- Affiliations
- Salk Institute for Biological Studies (US)
- Beth Israel Deaconess Medical Center (US)
- Venue
- Nature
- Published
- 2006-05
- Volume
- 441
- Issue
- 7092
- Pages
- 424-430
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2144323242
- Cited by
- 2,019
- References
- 86
- Citations by year
- 2026: 26 · 2025: 40 · 2024: 48 · 2023: 68 · 2022: 68 · 2021: 77 · 2020: 91 · 2019: 74 · 2018: 95 · 2017: 99 · 2016: 109 · 2015: 146 · 2014: 119 · 2013: 153 · 2012: 143
- FWCI
- 9.82
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- National Institute of General Medical Sciences (R01GM041890)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Keywords
- Ras signaling, PI3K signaling, mTOR signaling, tumour cell growth, nutrient sensing, amino acids, glucose, oxygen availability, cancer mutations, carcinogenesis, cell survival
- MeSH terms
- Animals, Humans, Neoplasms, Protein Kinases, Signal Transduction, ras Proteins, Phosphatidylinositol 3-Kinases, Cell Growth Processes, TOR Serine-Threonine Kinases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.